Invasive fungal sinusitis-analysis of management scenario

Prishni Devi Dutta, B. P. Belaldvar, R. N. Patil


Background: The objective of the study was to analyse the outcomes after therapeutic treatment of invasive fungal sinusitis.

Methods: A cross-sectional study consisting of 30 patients from January 2015-December 2005 in Jawaharlal Nehru medical college, department of ENT, Belagavi. Antifungal drugs were used like Amphotericin B-both non-liposomal & liposomal variety, and analysis of various parameters like its duration, efficacy and dosage was done in determining the prognosis.  

Results: The liposomal type of amphotericin B (AmBisone), which was used in 23 patients (76.6%) had a response rate of 65% and failure rate of 26%, with minimum dose of 50 mg/day to maximum dose of 200 mg/day. The maximum number of days used was for 46 days in 18 cases, which showed the effectiveness in controlling the infection. Amphotericin B deoxycholate (Fungizone) was used in 6 patients (20%) with response rate of 50% and failure rate of 33.3% and maximum dose given was 25 mg/day keeping a track of the renal profile. The total duration of treatment with Fungizone was for 14 days.

Conclusions: Along with surgical intervention, we were able to combat this fatal disease in 56% patients which was the overall survival rate and liposomal variety was preferred as majority of the patients had deranged renal parameters on presentation. But certain constraints like non-affordability by poor patients, cost-effectiveness on long term usage, were there. So further studies about the availability of more safer and affordable antifungals should be done. 


Invasive fungal sinusitis, Antifungals, Amphotericin B

Full Text:



Morgan J, Warnock D. Mycotic diseases of the Paranasal sinuses. Scott-Brown’s Otorhino-laryngology Head and Neck surgery. 7th ed. London: Hodder Arnold; 2008: 216.

Fliickiger U, Marchetti O, Bille J, Eggimann P, Zimmerli S, Imboff A, et al. Treatment options of invasive fungal sinusitis in adults. Swiss Med Weekly. 2006;136:447-63.

Ferguson B. Fungal Rhinosinusitis A Spectrum of Disease. The Otolarngologic Clin North America. 2000;33(2):227-454.

Chakrabarti A, Chatterjee S, Das A, Panda N, Shivaprakash M, Kaur A, et al. Invasive zygomycosis in India experience in a tertiary care hospital. Postgrad Med J. 2009;85:573–81.

Kasapoglu F, Coskun H, Ozmen O, Akalin H, Ener B. Acute invasive fungal rhinosinusitis: Evalutaion of 26 patients treated with endonasal or open surgical procedures. Otolaryngol Head Neck Surg. 2010;143:614-20.

Shoham S, Magill S, Merz W, Gonzalez C, Seibel N, Buchanan W, et al. Primary treatment of zygomycosis with liposomal amphotericin B analysis of 28 cases. Medical Mycol. 2010;48:511–7.

Idoko K, Gomes I, Sharma P. Rhinocerebral Mucormycosis in patient with Acquired Immunodeficiency Syndrome. Infecti Dis Clin Practice. 2011;19(6):431-2.

Roden M, Zaoutis T, Buchanan W, Knudsen T, Sarkisova T, Schaufele R, et al. Epidemiology and Outcome of Zygomycosis: A review of 929 cases. Clin Infect Dis. 2005;41:634-53.

Bongiovanni M, Ranieri R, Ferrar D, Codeca C, Tartaro T, Uzie L. Prolonged survival of an HIV-infected subject with severe lymphoproliferative disease and rhinocerebral mucormycosis. J Antimicrob Chem. 2007;60(1):192-3.

Greenberg R, Scott L, Vaughn H, Ribe J. Zygomycosis (mucormycosis): emerging clinical importance and new treatments. Current Opinion Infect Dis. 2004;17:517–25.